Three-year clinical results of the Axxess Biolimus A9 eluting bifurcation stent system: the DIVERGE study
Ian Buysschaert, Christophe L Dubois, Joseph Dens, John Ormiston, Stephen Worthleys, Dougal McClean, Jan Paul Ottervanger, Ian Meredith, Neal Uren, William Wijns, Rob Whitbourn, Roxana Mehran, Alexandra J Lansky, Marzena Bichalska, Susanne Meis, Stefan Verheye
EuroIntervention | EUROPA EDITION | Published : 2013
AIMS: To report the three-year clinical outcome of the Axxess™ stent, a nitinol self-expanding Biolimus A9™ eluting stent for treatment of de novo coronary bifurcation lesions. The Axxess stent is a new-generation drug-eluting stent that might offer advantages in terms of improved clinical outcomes and safety profile in bifurcation lesion stenting. METHODS AND RESULTS: The DIVERGE study was a multicentre, prospective, single-arm trial. The primary endpoint was the cumulative rate of major adverse cardiac events (MACE), a composite of all-cause death, myocardial infarction (MI), and ischaemia-driven target lesion revascularisation (TLR) at one, two and three years. Secondary safety endpoints ..View full abstract
This trial was supported by Devax, Inc., Lake Forest, CA, USA, whose assets were acquired by Biosensors International Group.